Neurocrine Biosciences, Inc. reported significant financial performance for the third quarter of 2025, with total revenues reaching $794.9 million, a 28% increase from $622.1 million in the same period of 2024. This growth was primarily driven by net product sales of $789.9 million, which included $686.6 million from INGREZZA and $98.1 million from CRENESSITY, the latter being a new addition following its launch in December 2024. The company's net income for the quarter was $209.5 million, up from $129.8 million a year earlier, resulting in earnings per share of $2.11, compared to $1.28 in the prior year.
In comparison to the previous fiscal period, Neurocrine's operating expenses increased to $555.9 million from $438.3 million, largely due to heightened research and development costs, which rose to $250 million from $195 million. The increase in R&D spending reflects the company's commitment to advancing its pipeline, including ongoing Phase 3 studies for direclidine and osavampator. Additionally, selling, general, and administrative expenses also saw a rise, totaling $291.6 million, up from $234.3 million, as the company expanded its commercial organization to support the growth of its product portfolio.
Operationally, Neurocrine has made strategic moves to enhance its market position. The company initiated two Phase 3 clinical studies for direclidine in schizophrenia and a Phase 3 study for osavampator in major depressive disorder. Furthermore, the company expanded its sales teams for INGREZZA and CRENESSITY, aiming to maximize commercial momentum. As of September 30, 2025, the company reported total current assets of $2.16 billion, up from $1.72 billion at the end of 2024, indicating a strong liquidity position.
Neurocrine's customer base remains concentrated, with three customers accounting for a significant portion of total gross product sales. Customer A represented 41% of sales, while Customer B and Customer C accounted for 28% and 17%, respectively. The company also reported an increase in accounts receivable, reflecting higher sales volumes. As of the end of the third quarter, Neurocrine had cash and cash equivalents of $340.2 million, an increase from $233 million at the end of 2024, bolstering its financial flexibility.
Looking ahead, Neurocrine Biosciences anticipates continued growth driven by its expanding product portfolio and ongoing clinical trials. The company has authorized a $500 million share repurchase program, reflecting confidence in its financial health and commitment to returning value to shareholders. With a strong pipeline and strategic investments in R&D and commercial operations, Neurocrine is well-positioned to capitalize on market opportunities in the coming quarters.
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences is a biopharmaceutical company specializing in neuroscience. It develops and commercializes treatments for neuropsychiatric, neurological, and neuroendocrine disorders, including FDA-approved drugs like INGREZZA for tardive dyskinesia and Huntington's chorea, and CRENESSITY for congenital adrenal hyperplasia. The company focuses on innovative pipelines across small molecules, peptides, proteins, antibodies, and gene therapies, serving global markets with a competitive edge in rare and underserved neurological conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.